Notably, post-infection treatment with the recently described HSF1-inhibitor DTHIB/SISU-102, which selectively targets nuclear HSF1, was found to be highly effective in inhibiting sHCoV and SARS-CoV-2 omicron BA.1 replication, remarkably reducing the production of HCoV progeny particles in lung cells. This evidence concerns the gene HSF1 and infection.